Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real‐life Experience
The Laryngoscope · 2025-05 · 135 (5) · 1628-1635
DOI: 10.1002/lary.31948 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Laryngoscope, online erschienen am 09.12.2024. Verfasst von Sante De Santis und 2 weiteren Autor:innen. Beteiligte Einrichtung: ENT Department, SS. Annunziata Hospital, Cosenza, Italy. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Rhinitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Objective
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a challenging condition often managed with biologic therapies. This study compares the clinical effects and response times of dupilumab, omalizumab, and mepolizumab in Italian patients with severe uncontrolled CRSwNP.
Methods
This bicentric, retrospective study included 33 patients treated at two Italian hospitals between April and December 2023. Inclusion criteria followed EPOS 2020 guidelines, focusing on adults with bilateral polyposis, history of endoscopic sinus surgery, and evidence of type 2 inflammation. Patients self‐administered biologics according to AIFA protocols. Outcomes were assessed using SNOT‐22 for quality of life, Nasal Polyp Score (NPS) for polyp size, and Sniffin’ Sticks‐12 for olfactory function at baseline, 4 weeks, 3, 6, and 9 months.
Results
All three treatment groups (dupilumab, omalizumab, mepolizumab) showed significant improvements in SNOT‐22 scores from baseline to 9 months, with no significant differences between groups. Dupilumab showed the most rapid and sustained improvement in NPS, with significant reductions observed from 4 weeks onward. Both omalizumab and mepolizumab showed significant NPS reductions by 6 months. Olfactory function improved significantly in the dupilumab group, with a notable decrease in anosmic patients from 64.3% to 28.6% at 9 months. Asthma control, measured by Asthma Control Test (ACT) scores, improved across all groups.
Conclusion
Dupilumab, omalizumab, and mepolizumab significantly improve quality of life and reduce nasal polyp size in CRSwNP patients, with dupilumab showing the fastest response. These findings support the effectiveness of biologics in real‐world settings for managing severe CRSwNP. Level of Evidence 3 Laryngoscope , 135:1628–1635, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ENT Department, SS. Annunziata Hospital, Cosenza, Italy.
- Interventional Radiology, SS. Annunziata Hospital, Cosenza, Italy.
- ENT Department, Misericordia Hospital, Grosseto, Italy.
ORCID-Profile: Sante De Santis, Stefania Galassi, Jacopo Cambi
Zitieren
APA
De Santis, S., Galassi, S., & Cambi, J. (2025). Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real‐life Experience. The Laryngoscope, 135(5), 1628-1635. https://doi.org/10.1002/lary.31948
Vancouver
De Santis S, Galassi S, Cambi J. Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real‐life Experience. The Laryngoscope. 2025;135(5):1628-1635. doi:10.1002/lary.31948
BibTeX
@article{DeSantis2025,
author = {De Santis, Sante and Galassi, Stefania and Cambi, Jacopo},
title = {Clinical Effects and Response Time of Biological Drugs in Chronic Rhinosinusitis with Nasal Polyps Patients: Real‐life Experience},
journal = {The Laryngoscope},
year = {2025},
volume = {135},
number = {5},
pages = {1628--1635},
doi = {10.1002/lary.31948}
}
EUVIMED